CD274 molecule. Every medicine in our data that ChEMBL or the Guide to Pharmacology records as acting on this protein, with the source for each and its current clinical trials on this site.
| Medicine | How it acts | Source | Current trials here |
|---|---|---|---|
| Durvalumab CHEMBL3301587 |
Programmed cell death 1 ligand 1 inhibitor Inhibitor Antibody |
ChEMBL only | 216 |
| Atezolizumab CHEMBL3707227 |
Programmed cell death 1 ligand 1 inhibitor Inhibitor Antibody |
ChEMBL only | 175 |
| Adebrelimab CHEMBL4297828 |
Programmed cell death 1 ligand 1 inhibitor Inhibitor Antibody |
ChEMBL only | 151 |
| Avelumab CHEMBL3833373 |
Programmed cell death 1 ligand 1 other Other Antibody |
ChEMBL only | 31 |
| Envafolimab CHEMBL4298006 |
Programmed cell death 1 ligand 1 binding agent Binding agent Antibody |
ChEMBL only | 23 |
| Sugemalimab CHEMBL4594535 |
Programmed cell death 1 ligand 1 binding agent Binding agent Antibody |
ChEMBL only | 4 |
| Danburstotug CHEMBL4650423 |
Programmed cell death 1 ligand 1 inhibitor Inhibitor Antibody |
ChEMBL only | 3 |
| KN046 CHEMBL4650483 |
Programmed cell death 1 ligand 1 inhibitor Inhibitor Antibody |
ChEMBL only | 3 |
| Bintrafusp alfa CHEMBL4298024 |
Programmed cell death 1 ligand 1 binding agent Binding agent Protein |
ChEMBL only | 2 |
“Both” means ChEMBL and the Guide to Pharmacology each record this medicine acting on this protein; “only” means one source records it and the other does not (often because it lists fewer secondary targets). The Guide to Pharmacology adds a medicine here only when this protein is its primary target. Medicines without a link have no page on this site yet.
| Disease | Medicines tested | Furthest trial phase |
|---|---|---|
| Biliary tract cancer | 7 | Phase 3 |
| Esophageal squamous cell carcinoma | 5 | Phase 3 |
| Gastric cancer | 5 | Phase 3 |
| Non-small cell lung carcinoma | 5 | Phase 3 |
| Breast cancer | 4 | Phase 3 |
| Cervical cancer | 4 | Phase 3 |
| Colorectal cancer | 4 | Phase 3 |
| Hepatocellular carcinoma | 4 | Phase 3 |
| Colorectal adenocarcinoma | 3 | Phase 3 |
| Endometrial cancer | 3 | Phase 3 |
| Fallopian tube cancer | 3 | Phase 3 |
| Gastric adenocarcinoma | 3 | Phase 3 |
| Gastroesophageal junction adenocarcinoma | 3 | Phase 3 |
| Head and neck squamous cell carcinoma | 3 | Phase 3 |
| Cancer | 2 | Phase 3 |
From ChEMBL's drug-disease records, which draw on trial registries. A trial phase is not an approval; approved uses are on each medicine's page from the regulators' own records.
Which medicines act on this protein comes from two independent, expert-curated sources: ChEMBL's mechanism-of-action records (via the Open Targets Platform) and the IUPHAR/BPS Guide to PHARMACOLOGY. Each row says which of them lists it. Data from them is shared here under their share-alike licences (CC BY-SA 3.0 and 4.0).
A job re-reads both sources every 30 days. Medicines are matched to our pages by exact name or a ChEMBL-curated synonym, and to the Guide to Pharmacology by ChEMBL ID or exact name, never by a close spelling. No AI drafting. See our methodology. The Open Targets data on this page was last retrieved on 30 Sep 2026. How every register is built: methodology · fixes we have made: corrections log.
